Immuron ^{Priced, Nasdaq: IMRN}

We are a clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies that we believe can address significant unmet medical needs. Our oral polyclonal antibodies offer targeted delivery within the gastrointestinal track but do not cross into the bloodstream, potentially leading to much improved safety and tolerability, without sacrificing efficacy. We believe that our two lead immunomodulator product candidates, IMM-124E and IMM-529, have the potential to transform the existing treatment paradigms for NASH (Non Alcoholic Steatohepatitis) and for Clostridium difficile, respectively. We also market an OTC product, Travelan, that is the only product approved as a preventative to Traveler's Diarrhea. Travelan is also based on the same technology. The safety profile of our compounds, which has a Generally Regarded as Safe status, enables us to commercialize our platform-derived products through a range of regulatory pathways, including prescription, medical foods, over-the-counter medicines and dietary supplements.